Seattle has positioned itself as the undisputed cancer research center in the United States, a factor that has even prompted a sitting vice president to visit the research hubs. Some of the research facilities in the region are decades old and have come up with grand theories about the disease. But the latest entrant into the hub’s research sphere in the name Seattle Genetics under the stewardship of Dr. Clay Siegell threatens to outdo them all with a breakthrough after another.
Just recently, the Siegall had its first drug approved by both the FDA and the European market drug agencies for the treat of three types of cancerous Lymphoma. Most importantly, Siegell’s invention in the name of Adcetris is currently undergoing final tests that would make it the sole treatment for the incurable Hodgkin Lymphoma. Currently, the drug is being used to treat three types of classical lymphoma.
What makes Clay Siegall’s discovery evolutionary
Clay believes that the medical benefits of the drug extend way beyond cancer treatment. He believes that the drug can also be used to treatment of non-cancer related illnesses. In line with this claim, Clay intimated that his firm is currently testing Adcetric’s efficiency of the in the treatment of more than 70 other diseases. If it passes FDA’s approval as the primary treatment for Hodgkin Lymphoma, Adcetrics will be one of the most effective cancer treatment options available thus further igniting the already glowing hope for a cure to the cancer menace.
Clay’s entry into cancer research
The current achievements by clay in the field of medicine are just a reflection of years of hard work in the field of cancer research. After graduating with a degree in Zoology, Clay furthered his interests in research with a Ph.D. in genetics from George Washington University. He was introduced to cancer research at the National Cancer Institute where he started his career before furthering this passion with the Squibb Pharmaceutical Research Institute where he worked for over five years.
Having established a significant cancer research base with these institutions, Clay Siegall set out to build a private research facility, The Seattle Genetics that he has headed for more than a decade in the development of Adcentris and 12 other equally potent drugs that are in currently in various testing stages.